Status: Recruiting
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Participants needed: 12
Trial details
Phase: Phase 1Biological sex: AllType: InterventionalSponsor: iCell Gene TherapeuticsUpdated: Sep 16, 2025Locations: 2
Eligibility criteria
Signed written informed consent; Patients volunteer to participate in the resear... [+4]
Patients declining to consent for treatment [+3]